Derived, not asserted. Three things happened between 5 July and 10 September 2026 that together decide what an orthopaedic practice is selling for the next decade. Here is the derivation, the arithmetic, the constraints, and what would prove it wrong.
Start with the only premise that does any work. A selection layer — a search engine, a directory, a referral network, an answering system — can only sort on attributes it can read. Everything else about you is prose, and prose is not comparable.
This is not a claim about artificial intelligence. It is a claim about ranking functions, and it has been true of every marketplace ever built. What is new is that the selection layer for surgical care now exists, and it has exactly one populated column.
On 1 September 2026, two companies announced a partnership routing musculoskeletal patients end to end. By their own figure, roughly 15% of members progress past conservative care; those members are guided to participating orthopaedic providers with a bundled price up front, capable of combining surgeon, facility and anaesthesia into a single number.
The mechanism is named in the vendor's own product list: navigation infrastructure, powered by a named agent, used to route patients to transparently priced care. A named agent, in production, selecting which orthopaedic surgeon a patient reaches.
And the network is opt-in, which reads as protection until you apply the difference between a list and an answer. A list has many winners. An answer has one, or maybe three. Absence from the machine-readable set does not make you second-best; it leaves you out of the answer.
The ACCESS Model (Advancing Chronic Care with Effective, Scalable Solutions) is a CMS Innovation Center model under §1115A of the Social Security Act. It began 5 July 2026 and runs ten years. Voluntary, Original Medicare, four clinical tracks — and one of them is musculoskeletal: chronic musculoskeletal pain.
It replaces activity payment with Outcome-Aligned Payments: a recurring payment for managing a qualifying condition, with full payment tied to achieving measurable outcome targets. For the MSK track those targets are validated patient-reported outcome measures of pain, mood and function.
And note the entry requirement. Participants must be Medicare Part B-enrolled organisations and must designate a physician Clinical Director responsible for clinical oversight and compliance. A named accountable clinician stops being a differentiator and becomes a condition of admission.
Source: cms.gov/priorities/innovation/innovation-models/access, read 10 September 2026 (page last modified 12 August 2026). Rolling application start dates are listed; the next one printed on that page falls after its own last-modified date, so ⚠ re-verify current dates against CMS before acting. Not legal or billing advice.
If agents are going to act inside clinical care, somebody has to say how they are held. The most serious public answer is ARPA-H's ADVOCATE programme — $62.7M over four years, building toward the first FDA-authorised clinical agentic system. ⛔ Nothing is FDA-authorised; authorisation is the programme's goal, with a first-of-its-kind package due within 24 months of award.
The architecture is the useful part:
That distinction is load-bearing and we state it as a limit on our own product: a human in the loop buys accountability, not accuracy. The evidence does not support “reviewed, therefore more accurate.”
Two payment mechanics decide which populations are reachable. Both are commonly modelled wrongly.
| Rule | Consequence |
|---|---|
| Monitoring in a global period may be billed only by practitioners not receiving the global payment | The operating surgeon is locked out of their own post-operative patient for the global period |
| One practitioner per patient per 30 days | The monthly slot is exclusive and may already be held by day 91 |
| RTM requires no established patient relationship (physiologic monitoring does) | Reach extends past the existing panel |
| Services may be delivered under general supervision | The only line that lets one clinician's accountability cover a population rather than a schedule |
And the arithmetic that settles it. The management line is twenty minutes per patient per calendar month, captured in roughly 53% of monitored months:
Impossible for a surgeon; ordinary for delegated staff. The binding constraint is hours, not dollars — which is why the valuable engineering is in preparing, routing, evidencing and attesting that interaction, never in the monitoring device.
The Ambulatory Specialty Model is the sharpest of the lot for this argument, because it is the one that scores a person rather than a hospital. CMS describes it plainly: “ASM is a mandatory model with five performance years that run from January 1, 2027, through December 31, 2031,” testing performance-based payment adjustments for specialists treating heart failure or low back pain.
Orthopaedic surgery is named in the low-back-pain cohort. Eligibility is historic: at least twenty attributed episodes from the relevant episode-based cost measure, in the calendar year two years before the performance year. A practice in a selected geography does not choose to participate.
Sources: cms.gov/priorities/innovation/innovation-models/asm and the ASM participant FAQ; CY2027 PFS proposed rule fact sheet and the Federal Register text. Read 10 September 2026. ⚠ Payment-adjustment magnitudes and participant counts circulate widely in secondary summaries — verify against the rule before quoting a percentage.
Four independent forces, pushing from different directions, all reward exactly one artifact.
| Force | What it demands |
|---|---|
| The routing layer | An outcome attribute a machine can read, or you are absent from the answer |
| ACCESS | Risk-adjusted outcomes published from Winter 2028; MSK scored on PROMIS PF, PROMIS PI and PGIC; a named physician Medical/Clinical Director required at entry. Referring clinicians may bill a Co-Management Payment (G0677 for MSK, $30 per service, up to 3× per 12-month care period) without joining the model. |
| ASM — mandatory, five performance years 1 Jan 2027 – 31 Dec 2031 | Scores an individual named clinician. The low-back-pain cohort explicitly includes orthopaedic surgery, neurosurgery, anaesthesiology, pain management, interventional pain management and PM&R, for clinicians with ≥20 attributed episodes in the calendar year two years prior. There is no opt-out. |
| Episode models — TEAM (live, 30-day, five surgical episodes) and CJR-X (90-day joint episodes including PT, from 2028) | A named clinician or institution scored across a period, on the perimeter of the operation. ⚠ TEAM began in 2026 but CMS states “Track 1 will have no downside risk and lower levels of reward for the first year, or up to three years for safety net hospitals” — so exposure arrives in the second performance year, not the first. ⛔ TEAM reaches knee, hip, ankle and spinal fusion — not shoulder, foot or hand. |
| Agent governance | An inspectable, per-claim rationale with a human accountable at escalation |
That is the asset. Not the model, not the app, not the device. Four different pressures converge on one artifact, which is what distinguishes a strategy from a list of initiatives.
| Layer | Its job in the artifact |
|---|---|
| chanio | Context. The corpus stays on the machine. The best clinical corpus is precisely the one that cannot be uploaded — so local-first is a working requirement, not a preference, and the method survives the model of the month. |
| SurgeonValue | Production. The surgeon-side line that generates the record as a by-product of work already being done — capture, coding audit, prior auth, registry, PROMs, monitoring. |
| ClinicalSwipe | Supply of signatures. Named licensed physicians who review and sign. ACCESS turns the named Clinical Director into an entry requirement, which turns signature supply into a market. |
| HarnessHealth | The gate. Every clinically meaningful output is held as DRAFT until a named physician attests it. No code path sends an unsigned draft to a patient, payer, or record. |
| HashCare | Proof. A SHA-256 fingerprint anyone can verify. This is what makes the record portable — the attestation remains checkable after the vendor that produced it is gone. |
| JointCoach · MSKvalue | The MSK instance. The patient-side collection and the episode economics for the one track ACCESS names. |
| Kinematic Joint | The clinical grounding. What the measurements mean, and why a patient-specific reference beat a universal one in three subspecialties independently. |
Read down that column and the estate is not a portfolio. It is one production line for one artifact, and each site is a station on it.
Capable companies already sell episode management into exactly these models — coordination and analytics across TEAM, CJR-X and ASM, patient-reported outcome collection taken on at risk, weekly cost tracking written back into the hospital's EHR, virtual therapy networks, digital pre- and post-operative programmes. That is real work, competently done, and worth paying for. A practice facing mandatory downside risk with no infrastructure should look hard at it.
We build a different thing, and the difference is worth stating precisely rather than competitively.
Both can be true at once. Many practices should buy episode management and keep their own attested, portable copy of what was signed in their name.
Everything above is a claim about payment mechanics and machine-readability. None of it survives contact with an organisation that has no owner for the pathway.
The clearest statement of this we have seen came as a comment on someone else's post, from a health-system chief strategy officer, about a large hospital innovation programme:
That is the same missing denominator that shows up everywhere in this field. Programmes publish the numerator — companies enrolled, pilots run, models deployed — and not the denominator, which is how many reached routine use and what happened to the rest. An absence of published failures is not evidence of none.
Applied here, honestly: an attested outcome record is worthless if no service line owns producing it, and no amount of correct reasoning about ACCESS, ASM or routing layers changes that. The binding constraint is almost never the technology, and we would rather say so than sell around it. Ask any vendor, including us, what the denominator is.
An argument that cannot fail is not an argument. Five things would break it:
Disclosure. SolvingHealth builds physician-attestation and remote-monitoring infrastructure for orthopaedic practices. This argument favours the category we work in. Every primary source above is public; check them rather than us.
Limits we hold ourselves to. Nothing we build is risk-adjusted today, and nothing we publish ranks any provider. We do not claim a human reviewer makes AI output more accurate. We do not claim FDA clearance or authorisation for anything, and ⛔ nothing in ADVOCATE is FDA-authorised — that is the programme's goal. Payment figures vary by locality and year; none of this is billing or legal advice, and a compliance review is not optional.
Open questions we have not resolved. Whether software-conducted interaction counts toward the twenty-minute management requirement (we doubt it, and it sets the ceiling on the whole monitoring model). The code-level split of the monthly monitoring rate, which is why we publish no blended per-patient figure. Current ACCESS application dates, which must be re-verified against CMS.
Sources read 9–10 September 2026: cms.gov (ACCESS, TEAM, episode models) · arpa-h.gov (ADVOCATE) · telehealth.hhs.gov (remote monitoring billing) · the routing partnership announcement on the vendors' own newsroom. Where a claim did not verify, it is not on this page.